In a pre-clinical study using SCID-rab mice, it was demonstrated that anti-DKK1 decreased osteoclastogenesis and promoted new bone formation by stimulating osteoblast activity, in both myeloma-involved and uninvolved bones [186]. This evidence concerns the gene AGFG1 and plasma cell myeloma.